GlaxoSmithKline Price To Sales Ratio vs Capex To Operating Cash Flow Analysis
GSK Stock | USD 43.50 0.15 0.35% |
GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC ADR latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC ADR is a good investment. Please check the relationship between GlaxoSmithKline PLC Price To Sales Ratio and its Capex To Operating Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Price To Sales Ratio vs Capex To Operating Cash Flow
Price To Sales Ratio vs Capex To Operating Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC ADR Price To Sales Ratio account and Capex To Operating Cash Flow. At this time, the significance of the direction appears to have very week relationship.
The correlation between GlaxoSmithKline PLC's Price To Sales Ratio and Capex To Operating Cash Flow is 0.2. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Operating Cash Flow in the same time period over historical financial statements of GlaxoSmithKline PLC ADR, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Price To Sales Ratio and Capex To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of GlaxoSmithKline PLC ADR are associated (or correlated) with its Capex To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Operating Cash Flow has no effect on the direction of Price To Sales Ratio i.e., GlaxoSmithKline PLC's Price To Sales Ratio and Capex To Operating Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.2 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing GlaxoSmithKline PLC ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on GlaxoSmithKline PLC sales, a figure that is much harder to manipulate than other GlaxoSmithKline PLC ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Capex To Operating Cash Flow
Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although Enterprise Value Over EBITDA will most likely fall to 7.90.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 784M | 879M | 775M | 502.2M | Depreciation And Amortization | 2.6B | 2.4B | 2.3B | 1.2B |
GlaxoSmithKline PLC fundamental ratios Correlations
Click cells to compare fundamentals
GlaxoSmithKline PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GlaxoSmithKline PLC fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 79.7B | 80.4B | 79.1B | 60.1B | 59.0B | 32.8B | |
Short Long Term Debt Total | 30.5B | 27.2B | 24.2B | 21.0B | 18.0B | 11.0B | |
Other Current Liab | 755M | 765M | 958M | 2.3B | 14.3B | 15.0B | |
Total Current Liabilities | 24.1B | 22.1B | 23.7B | 22.8B | 21.1B | 11.2B | |
Total Stockholder Equity | 12.0B | 14.6B | 15.1B | 10.6B | 13.3B | 14.0B | |
Property Plant And Equipment Net | 11.3B | 11.0B | 10.7B | 9.6B | 10.0B | 7.2B | |
Net Debt | 25.8B | 20.9B | 19.9B | 17.3B | 15.1B | 8.3B | |
Accounts Payable | 14.9B | 15.8B | 17.6B | 16.3B | 3.7B | 6.2B | |
Cash | 4.7B | 6.3B | 4.3B | 3.7B | 2.9B | 2.7B | |
Non Current Assets Total | 60.2B | 60.2B | 60.4B | 39.4B | 40.4B | 20.9B | |
Non Currrent Assets Other | 1.2B | 1.1B | 1.8B | 5.3B | 634M | 1.1B | |
Cash And Short Term Investments | 4.8B | 6.4B | 4.3B | 7.9B | 5.2B | 4.0B | |
Common Stock Shares Outstanding | 4.0B | 4.0B | 3.2B | 4.1B | 4.1B | 2.2B | |
Liabilities And Stockholders Equity | 79.7B | 80.4B | 79.1B | 60.1B | 59.0B | 32.8B | |
Non Current Liabilities Total | 37.3B | 37.5B | 34.1B | 27.2B | 25.1B | 14.3B | |
Inventory | 5.9B | 6.0B | 5.8B | 5.1B | 5.5B | 3.0B | |
Other Stockholder Equity | 5.2B | 4.9B | 4.9B | 5.1B | 3.2B | 2.9B | |
Total Liab | 61.3B | 59.6B | 57.8B | 50.1B | 46.2B | 25.5B | |
Property Plant And Equipment Gross | 10.3B | 11.0B | 10.7B | 9.6B | 20.2B | 21.2B | |
Total Current Assets | 19.5B | 20.2B | 18.7B | 20.8B | 18.6B | 11.9B | |
Capital Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Short Term Debt | 6.9B | 3.7B | 3.6B | 4.0B | 2.8B | 2.2B | |
Common Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Retained Earnings | 5.1B | 6.8B | 7.9B | 4.4B | 7.2B | 7.6B | |
Accumulated Other Comprehensive Income | 641M | 1.6B | 642M | (48M) | 1.6B | 1.7B | |
Intangible Assets | 31.0B | 29.8B | 30.1B | 14.3B | 14.8B | 11.4B | |
Other Liab | 13.7B | 14.1B | 13.5B | 10.2B | 11.7B | 14.2B | |
Long Term Debt | 22.6B | 23.4B | 20.6B | 17.0B | 14.2B | 17.5B | |
Good Will | 10.6B | 10.6B | 10.6B | 7.0B | 6.8B | 5.3B | |
Other Current Assets | 1.6B | 617M | 525M | 7.7B | 561M | 533.0M | |
Property Plant Equipment | 11.3B | 11.0B | 10.7B | 9.6B | 8.7B | 9.7B | |
Current Deferred Revenue | 1.4B | 1.8B | 1.6B | 299M | 222M | 233.1M | |
Other Assets | 5.1B | 5.3B | 6.9B | 6.9B | 7.9B | 5.4B | |
Net Receivables | 7.1B | 7.3B | 8.0B | 7.1B | 7.4B | 6.5B | |
Net Tangible Assets | (30.1B) | (25.8B) | (25.6B) | (10.8B) | (12.4B) | (13.0B) | |
Short Long Term Debt | 6.7B | 3.5B | 3.4B | 3.8B | 2.7B | 4.3B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.59 | Earnings Share 2.73 | Revenue Per Share 15.15 | Quarterly Revenue Growth 0.059 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.